ArticleBlood research2020
Thromboprophylaxis after bariatric surgery.
Article in Blood research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Enoxaparin 40 mg Versus 60 mg for Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacologic and Clinical Outcomes.Obesity surgery · 2026Pooled it
- Pooled it
- Impact of Intraoperative Ketamine on Postoperative Analgesic Requirement Following Bariatric Surgery: a Meta-analysis of Randomized Controlled Trials.Obesity surgery · 2021Pooled it
- Oxidative Stress, Micronutrient Deficiencies and Coagulation Disorders After Bariatric Surgery: A Systematic Review.Antioxidants (Basel, Switzerland) · 2026Review
- Effects of sleeve gastrectomy on rivaroxaban pharmacokinetics, efficacy, and safety.Frontiers in pharmacology · 2026Article
- Predictive Factors for Pulmonary Embolism in Patients Undergoing Metabolic and Bariatric Surgery: Insights from the Latest MBSAQIP Data.Obesity surgery · 2025Article
- Analyzing the Adequacy of BMI-Tiered Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in the Bariatric Surgery Population Based on Anti-Factor Xa Assay Data.Obesity surgery · 2025Article
- Optimal Thromboprophylaxis in Laparoscopic Bariatric Surgery in a Private Third-Level Center in Mexico City.Cureus · 2025Article
- The clinical effect of endoscopic and open surgery in the treatment of thyroid cancer and their effect on the blood coagulation state: a comparative study.Annals of surgical treatment and research · 2024Article
- Assessing the Efficacy of Extended Postoperative Enoxaparin as Thromboprophylaxis for Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Prospective Analysis.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a known cause of morbidity and mortality after bariatric surgery. However, the data concerning appropriate thromboprophylaxis after bariatric surgery is uncertain. The objective of this study was to evaluate the efficacy and safety of extended duration thromboprophylaxis in post-bariatric surgery patients.
methodsWe conducted a retrospective study of consecutive patients who underwent bariatric surgery from November 2014 to October 2018 at King Fahad General Hospital in Jeddah, Saudi Arabia. All included patients were treated with extended duration thromboprophylaxis.
resultsWe identified 374 patients who underwent bariatric surgery during the study period. Of these, 312 patients (83%) were followed for at least 3 months. The most common type of surgery was a laparoscopic sleeve gastrectomy (N=357) and the median weight was 110 kg. The cumulative incidence of symptomatic postoperative VTE at 3 months was 0.64% (95% confidence interval, 0.20-1.52). All events occurred after hospital discharge. The most commonly used pharmacological prophylaxis (91%) for VTE prevention after bariatric surgery was enoxaparin 40 mg subcutaneously twice daily for 10-14 days after hospital discharge. There were no reported cases of bleeding or VTE related mortality after 3 months.
conclusionExtended thromboprophylaxis after bariatric surgery appears to be an effective and safe strategy for VTE prevention. Large prospective studies are needed to evaluate the optimal thromboprophylaxis regimen after bariatric surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.